Riyadh, The Kingdom of Saudi Arabia: Takeda, the global biopharmaceutical company, is pleased to announce a new strategic ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The findings suggest that "supportive care and management of geriatric vulnerabilities at baseline may improve outcomes and ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

More than 600 people signed up for St Joseph’s Medical Center’s 16th Run/Walk for Wellness, exceeding the cancer institute ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the years. While not all dividend stocks are the same, finding great companies ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

About the program: Project Equity is a 2021 initiative launched by the FDA's Oncology Center of Excellence to ensure that ...

Hematology-Oncology Associates of CNY has appointed Jennifer Pichoske as chief executive officer effective February 15, 2025.

Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, ...